Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

JW, thanks for posting.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
rocalinda Member Profile
 
Followed By 7
Posts 732
Boards Moderated 0
Alias Born 02/12/16
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
rocalinda   Monday, 10/21/19 06:00:26 PM
Re: JWC3 post# 215525
Post # of 231964 
JW, thanks for posting.

Mr. Knoll is betting on AVXL to the tune of 2% of his overall portfolio. One can only assume that he, an his research team, did extensive DD and disccussions with management, specifically Dr. M., before deciding that he belived the science and credibility and capability of the CEO before initiating his position in 2016. Worth notting that he has continued to increase his holding since. IMHO, he knows just a bit more about Anavex and biotech investing than some of the posters constantly spreading FUD on this MB. Easy call.
------

Knoll has been betting on Medivation for many years. He has been a major shareholder of Medivation since it was a penny stock in 2005, when Knoll first disclosed owning 15% of the company. To be prudent, Knoll has sold some of his Medivation shares since then, but the stock just kept rising as Medivation developed Xtandi, a $2 billion prostate cancer drug, in partnership with a Japanese company. Medivation’s stock has returned 9,664% since Knoll first disclosed his ownership in the company.


“It’s a very very significant position,” Knoll said in an interview, adding that his family trust invests in private companies and real estate in addition to U.S. stocks. “It has been my experience over the years that the way to make real money is to bet on very few companies that are well managed and have high potential and to stay with them as long as they execute.”

Who is Fred Knoll? Born in the U.S., Knoll, 60, says he was raised in Colombia and returned to the U.S. to attend the Massachusetts Institute of Technology. He got into the investment business after receiving an MBA from Columbia University, working as a tech analyst for Capital Group, Robert Fleming and General American Investors. Knoll struck out on his own in 1989, starting Knoll Capital Management, which invested his family trust’s money. For a period between 2001 and 2009, he also ran a fund for institutional clients, mostly in Europe. Knoll has always concentrated on small capitalization stocks. He invested in tech companies in the 1990s and gold and mining stocks in the early 2000s.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist